REG - RTW Biotech Opp. - Cancellation of Own Shares

RTW Biotech OpportunitiesAnnouncement

24/05/2024 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240524:nRSX8627Pa&default-theme=true

RNS Number : 8627P  RTW Biotech Opportunities Ltd  24 May 2024

LEI: 549300Q7EXQQH6KF7Z84

24 May 2024

RTW Biotech Opportunities Ltd

Cancellation of Own Shares

 

Following approval at the Annual General meeting held on 16 May 2024 the
Company has today cancelled 48,322,863 of its own shares that were previously
held by RTW Biotech Opportunities Operating Ltd ("RTW OpCo") for nil
consideration. Such Shares were issued to RTW Opco pursuant to the scheme of
reconstruction of Arix Bioscience plc ("Arix"), as described in the Company's
prospectus dated 5 January 2024.

 

Further details are set out below:

 

Number of shares held as treasury shares following this cancellation:
9,853,791

Total shares in issue excluding treasury shares following this cancellation:
336,113,649

 

The above figure of 336,113,649 may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the Company under
the FCA's Disclosure and Transparency Rules.

For Further Information:

 

 RTW Investments, LP                           +44 (0)20 7959 6361 biotechopportunities@rtwfunds.com
 Woody Stileman, Managing Director

 Krisha McCune, Director, Investor Relations

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund
focused on identifying transformative assets with high growth potential across
the biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSQKQBNKBKDDPB